L-826266 is a selective and competitive EP3 receptor antagonist. L-826266 can be used for convulsive disorders research In Vitro In adult rat hippocampal slices, L-826266 (1 μM) prevents the PGE2-induced decrease of Na+,K+-ATPase activity. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo L-826266 (0.01-1 nmol/site; i.c.v.; once) delays seizures, and increases the latency for clonic and generalized tonic-clonic seizures induced by PTZ . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Adult male Wistar rats (250-300 g) injected with Pentylenetetrazol (PTZ) Dosage: 0.01 nmol/site, 0.1 nmol/site or 1 nmol/site Administration: i.c.v.; once Result: Increased the latency for clonic and generalized tonic-clonic seizures induced by PTZ. Form:Solid IC50& Target:EP3